Effect of Teduglutide on Gastric Emptying in Healthy Subjects

Inclusion Criteria:

1. Informed of the nature of the study and have agreed to and are able to read, review,
understand, and sign the informed consent document prior to any screening assessments
being completed.

2. Completed the screening process within 30 days prior to check in

3. Adult males or females age 18 to 45 years in good health as determined by medical
history, physical examination, ECG, and laboratory tests

4. Women who are: (1) post-menopausal; (2) surgically sterilized, OR (3) of childbearing
potential with a negative pregnancy test at screening and check-in and who consent to
use an acceptable method of contraception for the duration of the study and for four
weeks following last dose of study drug.

Exclusion Criteria:

1. Allergy or sensitivity to acetaminophen

2. History of structural abnormality or pathology of the GI tract or diseases/conditions
which affect GI motility including the following:

Gastric, small bowel or colonic resection, Colon cancer or any GI Tract cancer
Inflammatory bowel disease, Irritable bowel disease, Diabetes Mellitus, Gallstones or
cholecystectomy, Appendectomy, hernia repair, benign polypectomy are not excluded, History
of Gilbert's Syndrome 3 History of hepatitis or pancreatitis 4 Evidence of any abnormal
hepatobiliary laboratory parameters (> ULN for serum ALT; AST; ALP; GGT; and/or total,
direct or indirect bilirubin) 5 Serum amylase or lipase above the upper limit of normal 6
Body mass index (BMI) > 30 kg/m2 7 Intention to use medication that potentially affects GI
tract motility 8 History of a viral or bacterial infection, allergy, other inflammatory
process or surgery within 3 weeks of the check-in day.

9 Clinical evidence or history (including that from medical and medication history,
physical examination, laboratory, ECG and any other available test results such as those
from medical imaging studies) of significant cardiovascular, respiratory, renal,
gastrointestinal, hematologic (eg, anemia), neurologic, psychiatric conditions or of any
disease that may interfere with the objectives of the study or with the subject
successfully completing the study 10 Presently taking prescription or over the counter
medication including products containing acetaminophen, vitamins, herbs or dietary
supplements, which cannot be discontinued. Prohibited medications must be discontinued at
least 7 days prior to check-in and all other medications and supplements must be stopped
at least 72 hours prior to check-in.

11 Current or recent history (within 12 months) of drug or alcohol abuse 12 Positive drug
or alcohol screen 13 Current or recent history (within 3 months) of use of tobacco
products 14 Positive urine cotinine screen 15 Abnormalities in clinical chemistry,
hematology, urinalysis or in any other laboratory variables 16 Positive results in any of
the virology tests of acute or chronic infectious human immunodeficiency virus (HIV) and
hepatitis virus infections 17 Pregnant or lactating females; positive beta human chorionic
gonadotropin (b-hCG) pregnancy test in females only 18 Special dietary requirements which
would preclude a subject's acceptance of a high fat or high caloric, standardized meal 19
Blood donation within 4 weeks of the check-in day 20 Participation in another clinical
trial with an investigational drug or device within the last month (if single dose) and at
least 3 months (if multiple dose) or within 10 times the half-life of the respective
investigational drug, whatever is longer, before the screening evaluation. For biologics
the minimum period is at least 6 months or the time of duration of the pharmacodynamic
effect or 10 times the half-life of the respective drug, whatever is longer, before the
screening evaluation.

21 Lack of ability or willingness to give informed consent